What happens when an altered state of consciousness becomes part of psychotherapy? We visited a new clinic in Vienna offering ketamine-assisted therapy. Dr. Claus Derganc showed us around and discussed the treatment’s potential, its risks, and how patients work through difficult experiences.

At ICPR 2024, we talked to Jamila Hokanson,from the Yale University School of Medicine, about how psychedelics might offer new hope for people living with obsessive-compulsive disorder (OCD).

At ICPR 2024, we talked to Leonie Schneider and Ian Roullier, co-founders and co-directors of the Psychedelic Participant Advocacy Network (PsyPAN) in the UK, about why patient voices matter in the development of psychedelic therapy.

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researcher Sandeep Nayak about clinical trials, common therapeutic factors, and how the field can better understand the mechanisms behind psychedelic-assisted treatment.

At ICPR 2024, we talked to Robert Jesse, from the Johns Hopkins University, about mystical experiences with psychedelics, their spiritual and cultural dimensions, and the value of community in supporting their responsible integration.

At ICPR 2024, we talked to Wim van den Brink, MD, PhD, Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam, about the potential of psychedelics to reduce compulsive thinking and support addiction treatment.

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researcher Sandeep Nayak about clinical trials, common therapeutic factors, and how the field can better understand the mechanisms behind psychedelic-assisted treatment.

At ICPR 2024, we talked to anthropologist and author Nicolas Langlitz about the current hype around psychedelics, their place in medicine and culture, and why he sees them as holding the promise of moksha in the age of soma.

Women make up more than half of the population, yet they remain significantly underrepresented in psychedelic research. At ICPR 2026, we spoke with neuroscientist Grace Blest-Hopley about the gender gap in psychedelic science, the importance of studying menstrual cycles, pregnancy, menopause, and women’s mental health, and how the field can become more inclusive and scientifically rigorous.

On 7 May 2026, policymakers, researchers, clinicians, people with lived experience, and civil society organisations gathered in Brussels for the inaugural meeting of the European Forum of National Psychedelic Societies. The meeting marked an important milestone in building a coordinated European movement to expand safe, evidence-based access to psychedelic-assisted therapies.